NSEDisclosure under SEBI Takeover Regulations30 Jun 2026 · 30 Jun 2026, 03:21 pm

Disclosure under SEBI Takeover Regulations

Jagsonpal Pharmaceuticals Limited · JAGSNPHARM

✦ AI SummaryRegulatory

Jagsonpal Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoters have not created any encumbrance over the shares of the company as on March 31, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Jagsonpal Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Attachments (1)

📄

team_sandeshc_23062026131250_37.pdf

pdf

Download →
View document text
April 09, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai-400 001 Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Dear Sir/ Madam, Subject: Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 In terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 we are hereby enclosing the Annual disclosures of our promoters under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the year ended on March 31, 2026 for compliance. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Docusign Envelope ID: 4C59C8B5-DB81-462E-B672-CB1E285CDBB7 Infinity Holdings Apex Fund and Corporate Services (Mauritius) Ltd 6th floor, Two Tribeca, Tribeca Central, Trianon, 72261, Mauritius April 06, 2026 The Manager The Manager BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Sub: Disclosure by Promoters of Listed Company under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir/Madam, Pursuant to the provisions of Regulation 31 (4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, We, Infinity Holdings along with persons acting with concert of Jagsonpal Pharmaceuticals Limited, hereby declare that we have not made any encumbrance of shares, directly or indirectly during the financial year ended March 31, 2026. Kindly take the above-mentioned information on your record. For Infinity Holdings Ahmad Tariq Hossanee Director Encl: as above Infinity Capital (Formerly known as Infinity Holdings Sidecar I) Infinity Portfolio Holdings The Audit Committee Jagsonpal Pharmaceuticals Limited Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, Delhi, 110020 The Company Secretary, Jagsonpal Pharmaceuticals Limited Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, Delhi, 110020 April 09, 2026 The Manager The Manager BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Bandra-Kurla Complex, Mumbai 400 001. Bandra (E), Mumbai 400 051. Scrip code: 507789 Scrip code: JAGSNPHARM Sub: Declaration under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir / Madam In terms of Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, Rajpal Singh Kochhar and Aresko Progressive Private Limited, the Promoters of the Jagsonpal Pharmaceuticals Limited (“Company”), based on the information received from other members of the promoter group of the Company (as listed in Annexure A hereto) hereby declare that the members of the promoter and promoter group of the Company have not created any encumbrance over the shares of the Company, directly or indirectly, as on March 31, 2026 Kindly take the same on record. Thanking You Rajpal Singh Kochhar For and on behalf of Aresko Progressive Private Limited The Audit Committee Jagsonpal Pharmaceuticals Limited Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, Delhi, 110020 Company Secretary Jagsonpal Pharmaceuticals Limited Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, Delhi, 110020 Annexure A S. Name person acting in concert Category No of shares 1. Rajpal Singh Kochhar Promoter 30,30,400 2. Aresko Progressive Private Limited Promoter 1,33,35,635 (Trustee of Aresko Progressive Trust, a in the capacity of representative partner of J&P Investments Partnership) 3. Prithipal Singh Kochhar Promoter Group 2,69,675 4. Inderpal Singh Kochhar Promoter Group 1,83,750 5. Ishpinder Kaur Kochhar Promoter Group 6. Rakshit Organisational Operations and Promoter Group Transformations Private Limited 7. Aresko Life Sciences Private Limited Promoter Group 8. Aresko Restaurants Private Limited Promoter Group 9. Aresko Services Limited Promoter Group 10. Aresko Family Private Limited Promoter Group 11. Aresko Realtors Private Limited Promoter Group 12. Sewara Buildtech Private Limited Promoter Group 13. Naari Pharma Private Limited Promoter Group 14. I. K. Enterprises Private Limited Promoter Group 15. Alga Hospitality Private Limited Promoter Group 16. Aresko Estates Private Limited Promoter Group 17. Bagri Fort Resorts Private Limited Promoter Group 18. Mahar Palace Hotel & Spa Private Limited Promoter Group 19. Kila Tatarpur Hotels Private Limited Promoter Group 20. Suvinys Developers Private Ltd Promoter Group 21. Jaswant Singh Kochhar Foundation Promoter Group 22. RPSK Partners LLP Promoter Group 23. Sewara Partners LLP Promoter Group 24. Aresko Associates LLP Promoter Group 25. Aresko Pharma LLP Promoter Group 26. Aresko Global LLP Promoter Group 27. Sewara Realtech LLP Promoter Group 28. RPSK Strategic LLP Promoter Group 29. Y Johnson LLP Promoter Group 30. Aresko Management LLP Promoter Group 31. Aresko Properties LLP Promoter Group 32. Sewara Management LLP Promoter Group 33. RPSK Realtech LLP Promoter Group 34. Aresko Progressive Trust (Represented by Promoter Group Trustee, Aresko Progressive Pvt. Ltd) 35. Aresko Family Trust Promoter Group 36. Aresko Realtors Trust Promoter Group 37. Sewara Buildtech Trust Promoter Group 38. Aresko Progressive Pvt. Ltd Promoter Group